Welcome to our dedicated page for Broadway Finl Del SEC filings (Ticker: BYFC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Community banks like Broadway Financial Corporation (BYFC) pack capital ratios, Community Reinvestment Act data, and credit-loss details into dense filings that can stretch beyond 200 pages. Tracking when executives buy shares or when loan delinquencies spike shouldn’t require forensic accounting skills.
Our platform solves that problem. Stock Titan’s AI reads every Broadway Financial quarterly earnings report 10-Q filing and Broadway Financial annual report 10-K simplified, extracting net interest margin shifts, allowance builds, and segment performance in plain language. You’ll see Broadway Financial Form 4 insider transactions real-time, so spotting fresh Broadway Financial insider trading Form 4 transactions happens before the market reacts. Need context on a sudden dividend change? The latest Broadway Financial 8-K material events explained appears within minutes of hitting EDGAR—complete with AI-generated highlights.
- Compare loan growth trends quarter over quarter without sifting through footnotes.
- Monitor Broadway Financial executive stock transactions Form 4 to gauge management sentiment.
- Review Broadway Financial proxy statement executive compensation summaries to understand incentive alignment.
Every document�10-K, 10-Q, 8-K, Form 4, DEF 14A—lands here with real-time updates and AI-powered summaries that make Broadway Financial SEC filings explained simply. Whether you’re understanding Broadway Financial SEC documents with AI for compliance, modeling, or quick due diligence, our actionable insights save hours and surface what drives value. Explore historical data, download filings, or dive into a concise Broadway Financial earnings report filing analysis—all in one place.
On 31 Jul 2025, SKYX Platforms Corp. (Nasdaq: SKYX) filed a Form 8-K to furnish (not file) a press release dated the same day (Exhibit 99.1). The release contains preliminary, unaudited revenue for Q2 2025 (three months ended 30 Jun 2025) and a general business update, but no numerical figures are included in the 8-K itself.
Management emphasizes that the numbers remain subject to normal closing, internal review and external audit; final results could differ materially. Item 8.01 incorporates the Item 2.02 disclosure, and the exhibit is excluded from Section 18 liability because it is furnished. No other material events, transactions, or guidance changes are reported. Investors must await the forthcoming Form 10-Q for definitive financial statements.
Amneal Pharmaceuticals (AMRX) filed an 8-K disclosing a major refinancing package. On 24 Jul 2025 the company priced $600 million of 6.875% senior secured notes due 2032 at par in a Rule 144A/Reg S private placement. The note size was reduced from the previously announced $750 million.
Concurrently, subsidiary Amneal Pharmaceuticals LLC plans to enter a new $2.1 billion, seven-year term loan B facility, upsized by $300 million from prior guidance. Together, proceeds from the notes and the new term B loans will be used to refinance existing term B loans and fully repay amounts outstanding under the ABL facility, along with related fees and expenses. The note offering is not contingent upon closing of the new term loan; both transactions are expected to close 1 Aug 2025, subject to customary conditions.
The securities will not be registered under the Securities Act and are being offered only to qualified institutional buyers (Rule 144A) and non-U.S. persons (Reg S).
Form 4 overview: Director Laura Berner of Bolt Biotherapeutics (BOLT) reported a single equity-based transaction dated May 27 2025. She received a non-qualified stock option for 1,100 common shares at an exercise price of $6.40 per share. All figures give effect to the 1-for-20 reverse stock split that the company executed on June 6 2025.
Key terms of the grant:
- Vesting: Options vest on the earlier of May 27 2026 or the day immediately prior to the next annual meeting, subject to continued service.
- Change-in-control: The award vests in full upon a change-in-control event.
- Expiration: May 26 2035 (10-year life).
No shares were purchased or sold; the filing reflects compensation-related option issuance. Post-grant, Berner beneficially owns 1,100 derivative securities and no disclosed non-derivative common shares.
Corporate context: The recent reverse split consolidated each 20 common shares into one, reducing the share count and proportionally increasing exercise prices. Prior to the split, the grant was for 22,000 shares at $0.32 per share. The filing provides no additional financial or operational data.
FAQ
What is the current stock price of Broadway Finl Del (BYFC)?
What is the market cap of Broadway Finl Del (BYFC)?
What is the primary business of Broadway Financial Corporation?
How does Broadway Financial Corporation generate its revenue?
What role does City First Bank play within the organization?
What types of deposit products does the company offer?
How does Broadway Financial Corporation manage risk?
In what market segments does Broadway Financial Corporation operate?
How does the company differentiate itself from competitors?
What is the significance of the company's deposit funding model?
